Completed PHASE1 INTERVENTIONAL 5-arm NCT00642538

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

A Phase 1, Repeated Single-Dose, Double Blind, Randomized, Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal Female Subjects With Type 2 Diabetes Mellitus

Sponsor: Mannkind Corporation

Conditions Diabetes Mellitus, Type 2

Interventions MKC253 Inhalation Powder Technosphere Inhalation Powder subcutaneous injection

Updated 5 times since 2017 Last updated: Jun 12, 2012 Started: Feb 29, 2008 Primary completion: Sep 30, 2008 Completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by Mannkind Corporation and has accumulated 5 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mannkind Corporation

Data source: Mannkind Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zuidlaren, Netherlands